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Morpholino-mediated SOD1 
reduction ameliorates an 
amyotrophic lateral sclerosis 
disease phenotype
M. Nizzardo1, C. Simone1, F. Rizzo1, G. Ulzi1, A. Ramirez1, M. Rizzuti1, A. Bordoni1, 
M. Bucchia1, S. Gatti2, N. Bresolin1, G. P. Comi1 & S. Corti1
Neurotoxicity due to the accumulation of mutant proteins is thought to drive pathogenesis in 
neurodegenerative diseases. Mutations in superoxide dismutase 1 (SOD1) are linked to familial 
amyotrophic lateral sclerosis (fALS); these mutations result in progressive motor neuron death through 
one or more acquired toxicities. Interestingly, SOD1 is not only responsible for fALS but may also play 
a significant role in sporadic ALS; therefore, SOD1 represents a promising therapeutic target. Here, we 
report slowed disease progression, improved neuromuscular function, and increased survival in an  
in vivo ALS model following therapeutic delivery of morpholino oligonucleotides (MOs) designed to 
reduce the synthesis of human SOD1. Neuropathological analysis demonstrated increased motor 
neuron and axon numbers and a remarkable reduction in astrogliosis and microgliosis. To test this 
strategy in a human model, we treated human fALS induced pluripotent stem cell (iPSC)-derived 
motor neurons with MOs; these cells exhibited increased survival and reduced expression of apoptotic 
markers. Our data demonstrated the efficacy of MO-mediated therapy in mouse and human ALS 
models, setting the stage for human clinical trials.
Amyotrophic lateral sclerosis (ALS) is a fatal neurological disease characterized by the degeneration and loss 
of upper and lower motor neurons (MNs),which leads to paralysis and death within 3–5 years of diagnosis1. 
Currently, there is no effective treatment for this disease2. The majority of cases of ALS have no clear genetic link-
age and are referred to as sporadic (sALS), while 10% of cases are familial (fALS)3. Disease-causing mutations in 
various genes have been identified3. Mutations in the gene encoding for Cu/Zn superoxide dismutase 1 (SOD1) 
are relatively frequent4, accounting for 15% of sALS. Mutations in the SOD1 gene are linked to 20% of ALS cases. 
In these cases, the resulting progressive MN death is likely caused by one or more mutated SOD1-related toxici-
ties, as revealed by studies of transgenic rodent models5–8.
Recent evidence supports SOD1 as a toxic factor not only in fALS but also in sALS9. Indeed, changes in 
oxidation, demetallation, and other types of post-translational modifications are able to induce aberrant con-
formations of wild-type (WT) SOD1, which eventually lead to its acquisition of toxic functions comparable to 
those of fALS-associated SOD1 variants10–12. Due to a series of conformation-specific antibodies, SOD1 has been 
detected in spinal cord samples from ALS patients and SOD1 rodent models in an altered/abnormal conforma-
tion, conventionally referred to as misfolded, which may account for its inherent toxic nature10,13,14. Misfolded 
“mutant-like” forms of WT SOD1 have also been found in human post-mortem tissue from patients affected 
by sALS, suggesting a concrete pathogenetic role for these SOD1 variants10,13. This finding, along with reports 
that a reduction of both WT and mutant SOD1 in astrocytes derived respectively from sALS and fALS patients 
decreased astrocyte-derived toxicity towards MNs15, provides strong evidence for a pathogenic role of WT SOD1 
in sALS.
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Mutant SOD1 protein induces a pathogenic phenotype when specifically expressed in MNs16; however, it also 
contributes to disease onset and early disease progression when it is expressed in microglia16, astrocytes15,17, and 
oligodendrocytes18. These findings indicated that ALS is also a non-cell autonomous disease.
Therefore, the ability to interfere with toxic SOD1 overexpression and its misfolded form may lead to strong 
advances in the treatment of both the familial and sporadic forms of ALS. Antisense oligonucleotides (ASOs) 
seem to be a promising tool for achieving this goal. ASOs are nucleic acid analogs designed to trap RNAs by 
binding in a particular place and interfering with a specific biological process, such as splicing or translation19. 
They represent a promising therapeutic strategy for the treatment of various human disorders and are cur-
rently being tested in clinical trials. In preclinical and clinical trials, two different chemical variants of ASOs 
have been studied: the 2′ -O-methyl-modified phosphorothioate oligonucleotides or its more stable variant, 
2′ -O-(2-methoxyethyl)-modified phosphorothioate oligonucleotides; and the morpholino oligomers (MOs). 
MOs are analogs of natural nucleic acids in which the phosphorothioate-ribose backbone is replaced with a 
phosphorodiamidate-linked morpholine backbone that is refractory to metabolic degradation20. A Phase 1, 
randomized, first-in-human study with an ASO (2OMePS, ISIS 333611) against SOD1, which was delivered 
intrathecally to patients with SOD1 fALS, has been completed, demonstrating the safety and tolerability of this 
approach21.
Interestingly, impressive therapeutic rescue has been observed using MOs in another genetic motor neuron 
disease, spinal muscular atrophy (SMA), which is caused by mutations in the survival motor neuron 1 gene22–24. 
Recently, we confirmed this result by combining local and systemic administration of a 25-nt MO sequence 
(MO-10–34) in transgenic SMA mice. We effectively increased the expression of full-length SMN and observed 
robust neuromuscular improvement. Furthermore, in some cases, the survival rescue phenotype was essentially 
indistinguishable from that of healthy heterozygous mice25. While a direct comparison between methoxyethyl 
(MOEs) and MOs has not yet been performed for MNDs, it is likely that MOs will present greater advantages 
than MOEs. MOs exhibit low toxicity and high stability, a wide distribution in tissues, and in clinical trials, such 
as those for Duchenne Muscular Dystrophy, were associated with encouraging results that seem superior to those 
obtained using other ASOs19,26. While the safety and feasibility of the use of MOEs to reduce SOD1 have already 
been demonstrated in a phase 1 clinical trial21, the use of MOs has not yet been explored in the ALS field.
Here, we investigated MO sequences targeting SOD1 in rodent and human fALS models and demonstrated 
their efficacy in significantly reducing SOD1 levels and in improving the disease phenotype.
Results
Newly designed morpholino oligomers (MOs) against SOD1 effectively reduce protein levels 
in vitro. We designed two 25-nt MO sequences (MO1 and MO2) to target the human SOD1 gene. The MO 
sequences took into account the best predicted sequence of a bioinformatics tool27 and were designed both as 
Bare MOs (Bare-MOs) and with an octa-guanidine modification (Modified-MOs), which can increase the bio-
distribution of the MOs in vivo. The MOs were synthesized by Gene Tools using a method described elsewhere20. 
A scrambled MO (scr-MO) sequence was designed based on the best control sequence predicted by the bioin-
formatics tool (Gene Tools, www.genetools.com) and was used in all of the experiments as an internal control.
We performed an in vitro analysis of the two lead MO sequences to identify the most efficient one for further 
in vivo evaluation. We tested the Bare-MO sequences (which were suitable for the in vitro experiments) in dif-
ferent human cell lines by evaluating the reduction of SOD1 at different time points. We first nucleofected HeLa 
cells with 20 μ g Bare-MOs (MO1 or MO2) or scr-MOs, as suggested by the manufacturer’s protocol. We then used 
western blot to demonstrate a slight decrease in SOD1 protein levels at all time points with MO1 and a significant 
reduction (up to 60%) at all time points with MO2 (Supplementary Fig. 1A,B). Following in vitro delivery, MO2 
sequence was able to silence SOD1 in a human cell type.
MOs rescue apoptosis-mediated death in fALS induced pluripotent stem cell-derived motor 
neurons. We previously generated induced pluripotent stem cells (iPSCs) from healthy subject fibroblasts and 
from fALS-SOD1 patient fibroblasts with a non-viral, non-integrating method28,29. The iPSCs obtained showed 
markers of pluripotency and were able to differentiate into MNs (Fig. 1A,B). We tested the most effective MO 
sequence (MO2) in WT iPSCs (Fig. 1C), and we confirmed a strong decrease in SOD1 protein expression in all 
conditions (up to 70%). The same result was obtained for iPSC-derived MNs from a fALS patient with a L114P 
SOD1 mutation30 (60% reduction, Fig. 1D). To evaluate the effect of MO treatment on the pathological features 
of ALS and in particular on the phenotype of ALS-MNs in long-term culture, we examined MN survival in cul-
ture at 30 days. We observed a modest, but significant, increase in survival of the fALS MNs treated with MO2 
compared to the fALS scr-treated MNs (Fig. 1H; P < 0.01). No differences between wild-type (WT)-SCR and 
WT-MO2 MNs were observed, demonstrating the selective protective effect of MO on ALS cells (Fig. 1H).
Since mut-SOD1 proteins are known to be pro-apoptotic both in vitro and in vivo and that programmed cell 
death may be involved in the ALS neurodegenerative process31,32, we investigated whether the protective effect of 
MOs on MN survival was correlated with variation in the apoptotic pathway. Interestingly, we observed a reduc-
tion of the expression of the apoptotic markers Bax, caspase-3, and caspase-8 in MO2-treated fALS iPSC-derived 
MNs compared to the fALS scr-treated MNs (Fig. 1E–G) at 30 days in culture.
Bare-MOs effectively silence SOD1 in vivo in SOD1G93A mice. To confirm the results obtained 
in vitro, the two MO sequences were further evaluated in vivo, in the B6.Cg-Tg(SOD1-G93A)1Gur/J transgenic 
ALS mouse model, which carries a high copy number of the mutant human SOD1 allele containing the G93A 
mutation. The protocols used for the in vivo experiments were based on the results obtained in our previous 
experiments using MOs in an SMA mouse model25 and on published results obtained with antisense and shRNA 
against SOD133,34.
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Figure 1. MOs silence of SOD1 protein and rescue apoptosis-mediated death in fALS iPSC-derived MNs. 
(A) Immunocytochemical characterization of iPSC clones derived from human ALS fibroblasts. These iPSCs 
expressed pluripotency transcription factors including stem cell surface markers, TRA-1–60 (red) and SSEA-3 
(red). Blue, 4′ ,6-diamidino-2-phenylindole (DAPI) nuclear stain. Scale bar: 100 μ m. (B) After differentiation, 
iPSCs-derived MNs expressed specific motor neuronal marker, such as Islet-1 (red) and Hb9::GFP (green). 
Scale bar: 75 μ m. (C,D) Representative western blot (at least three independent experiments for each 
condition) and quantification analysis of SOD1 protein. Values are means ± SEM of SOD1:β -actin expression 
levels (n = 3), *P < 0.01, ANOVA. SCR: scr-treated cells; MO: MO-treated cells. (C) WT iPSCs treated with 
Bare-MO2 (20 ug) at 48 h and 72 h. (D) iPSCs-MNs derived from fALS patient treated with Bare-MO2 
(20 ug) at 48 h. (E–G) Immunocytochemical analysis and immunoreactivity score of iPSC-derived MNs at 
30 days in culture demonstrated that the signal of the specific apoptosis markers BAX (E), Caspase 3 (F) and 
Caspase 8 (G) (all green) is increased in fALS-MNs respect to WT-MNs and is reduced in MO-treated MNs 
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Because the octa-guanidine-modified MOs present a better biodistribution in weaned adult mice, this was 
the first chemical variant tested. However, the decrease in SOD1 protein in the spinal cords and brains of SOD1 
pups treated both locally and systemically was not significant (Supplementary Fig. 2A). This is in accordance 
with previously described research using octa-guanidine MOs against SMN225. Moreover, systemic injection of 
Modified-MOs failed to significantly silence SOD1 protein levels in the central nervous system (CNS) of symp-
tomatic SOD1G93A mice (Supplementary Fig. 2B). We observed a toxic effect of intracerebroventricular (ICV) 
injection in adult mice, both SOD1 mice and WT mice (data not shown), which limits the potential of this route 
of administration to increase the treatment effects in the CNS. The toxic effects of Modified-MOs were previ-
ously described in the literature23,25. We then tested the efficacy of the two Bare-MO sequences in SOD1 pups, 
following the injection protocol previously used for MOs in the SMAΔ 7 mouse model25. At 2 or 4 weeks after the 
injection, the treatment was completely successful, in both the brain (up to 90% reduction with MO2, Fig. 2A) 
and spinal cord (between 70% and 90% reduction at all of the time points, Fig. 2B). The SOD1 protein levels were 
strongly reduced, in peripheral tissues as well (up to 30% reduction, Fig. 2C), confirming the superior efficacy of 
MO2. Remarkably, Bare-MO2 decreased SOD1 levels by 80% in the brain and by 20% in the spinal cord of adult 
symptomatic SODG93A mice when injected ICV (Fig. 2D). Overall, we demonstrated the efficacy of the designed 
Bare-MO sequences, in particular MO2, in decreasing SOD1 protein levels in SOD1 mouse pups and adults.
MO treatment ameliorates neuromuscular dysfunction and prolongs the survival of SOD1 
mice. To assess the effects of MOs on survival and on the neuropathological phenotype of ALS, we treated 
a cohort of early symptomatic mice with Bare-MOs, combining ICV injection (once, at P80, 40 nMoles) and 
systemic injection (once per month starting from P80, 12.5 mg/kg) to deliver MO also in peripheral organs. The 
treatment ameliorated the ALS disease phenotype and increased the survival of SOD1 animals. The growth rates 
of the mice injected with both MO sequences, as measured by mean body weight, were increased compared to 
those of the scr-treated mice starting from P100 (Fig. 3A, at P140, P = 0.02). To analyze motor function, groups 
of mice were evaluated with the well-established rotarod test. Starting from P110, the treated animals exhibited 
significant improvement in rotarod performance relative to the scr-treated mice (Fig. 3B, P < 0.01, ANOVA), and 
some of them were able perform the test after P140, when all of the surviving scr-treated mice could not. Since 
the rotarod can be affected by the body weight, latency to fall was analyzed also using ANCOVA with body weight 
as the covariate (data not shown); however the differences were still significant (P < 0.05) between the groups. 
Administration of both MO sequences significantly extended survival, by 19 days or 21 days, compared to the 
survival of age-matched scr-treated mice (scr-treated mice, 148 ± 17 days; MO1 mice, 167.5 ± 8 days; MO1 vs scr 
P = 0.0007, χ 2 = 11.54; MO2 mice, 170 ± 11 days; MO2 vs scr P < 0.0001, χ 2 = 16.07, Fig. 3C). Considering both 
the later weight loss and later decrease in the rotarod performance of the MO-treated mice with respect to the 
scr-treated mice, the observed increase in survival is likely due to delayed disease onset. With respect to survival 
and neuropathological phenotype variation, the efficacy of the two MO sequences were comparable, although 
slightly better results were obtained with MO2, as shown in vitro.
MO-treated mice show MN and axonal protection and a reduction in inflammation. To evaluate 
the impact of MO treatment on the hallmarks of ALS and to understand the mechanisms of the resulting benefi-
cial effects, we analyzed the spinal cords of MO-treated mice and scr-treated mice in terms of neuropathological 
features. To determine whether SOD1 silencing prevented the loss of MNs, we analyzed the number of MNs in 
spinal cord sections and ventral spinal nerve roots at the end stage of the disease (Fig. 4A,B, P < 0.01). At this 
stage (P140), we observed a 60% loss of MNs in the scr-treated mice, whereas MN loss was significantly reduced, 
to 40%, by MO administration.
We next examined the neuroprotective effects of the treatment by counting the number of axons in the L4 
ventral root and found an increase of 35% in the MO2-treated animals with respect to the scr-treated animals 
(Fig. 4C, P < 0.01). Many studies have demonstrated the presence of an inflammatory response in ALS patients 
and in mutated SOD1 mice, suggesting the involvement of reactive astrogliosis and microglia in the disease 
pathogenesis (for a review, see35). Astrocytes modify their morphology, adopting hypertrophic nuclei and cell 
bodies with distinct, long, and thick processes with exhibiting increased expression of glial fibrillary acidic pro-
tein (GFAP), which is the main constituent of the intermediate filament system of adult astrocytes. The morpho-
logical and molecular modifications of astrocytes and microglia are associated with a shift from a neuroprotective 
to a neurodegenerative role towards MNs. Therefore, we analyzed whether a change in inflammatory reactions 
and astrogliosis and microglia occurred after MO treatment in lumbar spinal cords. Immunohistochemistry 
using the astrocyte markers GFAP and s100β demonstrated a sharp reduction in astrogliosis and activated micro-
glia in the MO-injected animals compared to the scr-treated mice (Fig. 5A–D, P < 0.001). Moreover, we detected 
a remarkable reduction in the expression of Iba-1, a marker of activated microglia, in the MO-injected animals 
respect to scr-treated samples. Scale bar: 100 μ m. Nuclei are stained with DAPI (blue). Quantification of the 
immunoreactivity score was measured with ImageJ software. *P < 0.01, values are means ± SEM. (H) WT-MNs 
and SOD1-MNs were treated with scr or MO2 at day 0 and counted for the survival analysis at day 1 and after 
30 days. The histograms show MNs counted at day 30 and 100% represents the number of MNs counted at day 
1 (10.000 cells). MO2 treatment increased survival of the SOD1-MNs compared to SOD1-scr-treated-MNs 
(*P < 0.01, Values are means ± SEM). No differences between WT-SCR and WT-MO2 treated MNs have been 
observed, demonstrating the selective protective effect on ALS cells. The histogram shown is representative 
of three independent trials. WT: healthy MNs; WT-SCR: healthy scr-treated MNs; WT-MO2: healthy MO2-
treated MNs; SOD1-SCR: scr-treated MNs; SOD1-MO: MO2-treated MNs.
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(Fig. 5E,F; P < 0.001). Overall, the sharp decrease of astrogliosis and microglial activation likely accounts for the 
protection of MNs and axons and, consequently, for the observed functional improvement.
MO treatment improves the size of myofibers and ameliorates defects in skeletal mus-
cle. SOD1G93A mice develop muscle atrophy, severe myopathy, and myofiber cell death. H&E-stained sec-
tions of quadriceps muscle demonstrated that the treatment positively affected degenerating skeletal muscle 
Figure 2. In vivo MO treatment silences the SOD1 protein. Western blot and relative quantifications of 
SOD1 protein in brain (A), spinal cord (B) liver (C) of treated SODG93A pups demonstrated decrease levels 
respect to scr-treated animals. Mice were treated ICV at P0 (80 μ g) and intraperitoneally (IP) at P0, P3 and P6 
(80 μ g/injections) and tissues were collected 2 or 4 weeks after the treatment. (D) Western blot and relative 
quantifications of SOD1 protein in brain and spinal cord of MO2 treated SODG93A adult mice (ICV at P80, 
40 nMoles, tissues harvested 2 weeks after the treatment) demonstrated decrease levels respect to scr-treated 
animals. The western blots are representative of at least three independent experiments for each condition. 
Values are means ± SEM of SOD1:β -actin expression levels (n = 5), *P < 0.01, **P < 0.001 (ANOVA). SCR:  
scr-treated mice, MO1: mice treated with Bare-MO sequence 1; MO2: mice treated with Bare-MO sequence 2.
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by improving myofiber morphology and organization and reducing the irregular connective tissue infiltrates 
detected in the quadriceps harvested from scr-treated mice (Supplementary Fig. 3).
MO reduces misfolded SOD1 protein. SOD1 can exist in an altered/abnormal conformation, referred 
to as misfolded SOD1, which is associated with the inherent toxic nature of SOD1 mutations10,36–38. A num-
ber of antibodies targeting misfolded SOD1 have recently been developed13,14,39. We tested two antibodies spe-
cific for the misfolded form of SOD1, the clone B8H10 and the clone C4F6, to investigate whether MOs act by 
reducing the expression of this non-native conformation of SOD1. We analyzed misfolded SOD1 levels using 
a non-denaturating gel in MO2-treated brains and spinal cords that were collected at different time points and 
compared them to the levels in scr-treated mice. We observed strong expression of the altered SOD1 protein 
conformation in all of the SODG93A samples and a reduction in its expression at all times point after MO treat-
ment (Fig. 6A). The decrease was confirmed by immunohistochemistry of the lumbar spinal cords of SOD1G93A 
scr-treated mice and SOD1G93A MO-treated mice (Fig. 6B). Misfolded SOD1 protein accumulated in fALS 
iPSC-derived MNs as well, and this accumulation was reduced after treatment (Fig. 6C). These preliminary data 
suggest that misfolded SOD1protein may be a therapeutic target and that MOs can reduce levels of misfolded 
SOD1 both in vitro and in vivo.
Discussion
In the current study, we have shown that MO-mediated silencing of mutant SOD1 expression in the CNS reverses 
an ALS disease phenotype in a transgenic mouse model, providing evidence of the remarkable therapeutic poten-
tial of this approach. Currently, there is a critical need for new and effective treatments for ALS. In fact, only 
one drug, Riluzole, is approved by the FDA as an ALS treatment, and Riluzole exhibits only a modest effect 
on survival (3-month increase in median survival)40. Given the accumulating data on the pathogenetic role of 
SOD1 in ALS, the development of therapeutic strategies has been focused on silencing mutant SOD1 protein 
to reduce its toxicity. Unfortunately, these strategies remain in the early stages. Antisense oligonucleotides and 
virus-delivered RNA interference have been investigated in rat and mouse ALS models33,34,41–44 with promising 
outcomes. However, many of these approaches were used to achieve SOD1 knockdown before disease onset. 
Figure 3. MO treatment improves neuromuscular function and survival in nmd mice. SOD1 mice were 
injected with Bare-MO (40 nMoles) at P85 with ICV injection and intravenously (IV, 12,5 mg/kg) once a week until 
the end of the disease. (A) The mean body weight of MO1 or MO2-treated mice resulted increased relative to  
scr-treated mice and significantly different at P140 (*P = 0,02, ANOVA, error bars show the SEM). (B) Rotarod test 
data. The performance of MO1 or MO2-treated mice, measured as latency to fall, was significantly increased respect 
to scr-treated mice (*P < 0.01, one way ANOVA) starting from P110. Error bars show the SEM. (C) Kaplan–Meier 
survival curves of MO1 or MO2-treated mice respect to scr-treated mice (MO1 vs scr P = 0,0007, χ 2 = 11,54; MO2 
vs scr P < 0,0001, χ 2 = 16,07). MO1 or MO2-treated mice, n = 11/group; scr-treated mice n = 18.
www.nature.com/scientificreports/
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Furthermore, they present technical difficulties or safety concerns that hamper their further development towards 
application in patients. Nevertheless, direct cerebrospinal fluid infusion of antisense oligonucleotides against 
SOD1 has been recently explored in a clinical trial21, demonstrating the tolerability and safety of the approach. 
Unfortunately, a limited reduction of SOD1 levels was obtained due to the low dosages used for safety reasons. 
Here, we exploited the peculiar chemistry, known stability, effectiveness, safety, and wide tissue distribution of 
MOs19,25,26 in the context of ALS. Due to these features, the MO approach promises to be superior to conventional 
phosphorothioate oligonucleotides. Compared to a viral approach, the use of MOs has a more attractive safety 
profile and the distinct advantage that the effects can be reversed by stopping the administration.
We demonstrated that local and systemic delivery of MOs effectively reduced SOD1, ameliorated pathological 
hallmarks, reduced disease duration prolonging survival in ALS rodents. We hypothesize that the decreasing 
Figure 4. MO treatment increases motor neuron and axon number. Spinal cords were collected at the end 
stage of the diseases (n = 3/group) (A) Representative Nissl stained MN features within the lumbar segment of 
spinal cord of MO2-treated mice and scr-treated mice. Scale bar: 70 μ m (upper panels), 50 μ m (bottom panels). 
(B) MN count in the lumbar spinal cord of MOs-treated, scr-treated and WT mice (n = 50 cross sections 
counted for each mouse, data represent the mean ± SD, *P < 0.01, ANOVA). (C) Quantification of myelinated 
axons in the L4 anterior roots in WT, MOs-treated, and scr-treated mice (the data represent the mean ± SD, 
*P < 0.01, ANOVA, n = 50 cross sections counted for each mouse). SCR: scr-treated mice; MO1: mice treated 
with Bare-MO sequence 1; MO2: mice treated with Bare-MO sequence 1, wt: wild-type mice.
www.nature.com/scientificreports/
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of SOD1 levels peripherally can contribute to the observed phenotype amelioration. We further demonstrated 
the efficacy of the MO therapy in a human disease model, using human fALS iPSC-derived MNs. Interestingly, 
the MNs derived from our fALS iPSC line exhibited decreased numbers in culture compared to WT MNs; this 
reduction was associated with an increase in apoptotic marker expression, in agreement with Kiskinis et al.31. 
MO treatment was able to reverse these two pathological characteristics. Several studies support the view that 
apoptosis plays a key role in the neurodegenerative processes of both fALS and sALS. Indeed, increased expres-
sion of pro-apoptotic proteins, such as Bax, Bad, and activated caspases, has been detected in the spinal cord in 
transgenic models of fALS as well as in human ALS patients, with or without SOD1 mutations (for a review, see32). 
One of the beneficial effects of MO may be due to the inhibition of apoptosis, although further studies are needed 
to investigate the exact mechanism of action.
We have achieved one of the most impressive reductions of SOD1 (up to 80% reduction) ever reported using 
a treatment in the ALS SOD1G93A mouse model after disease onset, which corresponds to the period when ALS 
is usually diagnosed in patients. These data represent a proof of concept that SOD1 silencing after disease onset, 
during clinically relevant points in the disease process, can be beneficial in rapid, progressive models of ALS, and 
demonstrate the promise of MO delivery during a symptomatic phase in terms of efficacy.
We delivered a single local injection of MOs in CNS, the effects of which usually lasted for a month. Thus, even 
more pronounced positive effects on survival and SOD1 reduction can be expected using continuous delivery 
with a mini-pump (which are clinically available) or with repeated administration.
The MO treatment resulted insubstantial protection of MNs and axons in the SOD1 mice. However, it is 
becoming increasingly clear that non-neuronal cells in the spinal cord also contribute to initial toxicity and dis-
ease progression in ALS35. In particular, the neuroinflammatory processes produced by microglia and astro-
cytes appear to be an important pathological hallmark of ALS pathology, as demonstrated in ALS patients and 
mutated SOD1 mice35. One of the advantages of the MO approach, with respect to other therapeutic strategies, 
is that it allows SOD1 targeting in both neuronal and non-neuronal cells in the CNS and can thus act on both 
the cell-autonomous and non-cell autonomous pathogenic mechanisms of ALS. One of the most striking effects 
Figure 5. MO treatment reduces micro- and macrogliosis. Expression of GFAP (red) (A) and s100β  
(green) (C) in the spinal cord of end stage MO2-treated mice respect to scr-treated mice and WT mice. 
(B,D) Quantification of GFAP and s100β positive cells. MO treatment significantly reduced the presence 
of astrocytes in the spinal cord of treated mice (**P < 0.001, ANOVA, mean values ± SEM from 5 
independent experiments performed in triplicate). (E) Expression of Iba1 (green) in the spinal cord of 
MO2-treated mice respect to scr-treated mice and WT mice. (F) Quantification of Iba1 positive cells; 
MO treatment significantly reduced the presence of microglial cells in the spinal cord of treated mice 
(**P < 0.001, ANOVA, mean values ± SEM from 5 independent experiments performed in triplicate). 
Nuclei are stained with DAPI (blue). Scale bar: 70 μ m. SCR: scr-treated mice; MO2: mice treated with 
Bare-MO sequence 2.
www.nature.com/scientificreports/
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of MO injection in the ALS mice was the significant reduction in astrogliosis and microgliosis, which is likely 
responsible for the treatment effectiveness after disease onset.
Glial cells are activated early in ALS, in both the human and rodent CNS, suggesting that neuroinflamma-
tion plays an important role in the cascade of events that trigger the death of MNs. Because these processes also 
occur in sALS, MO-mediated reduction of reactive astrocytosis and microgliosis is promising from a therapeutic 
perspective, especially when the ability of MOs to ameliorate MN survival by reducing apoptotic events is also 
considered. Moreover, broadly targeting regions of the brain and spinal cord enabled significant improvement of 
neuromuscular function, as demonstrated by improved muscle trophism and an increase in lifespan.
Translating these positive results to human cases of ALS, primarily SOD1fALS, is relatively feasible. Indeed, 
in our study, we demonstrated that MO-mediated reduction of SOD1 is safe and well tolerated in ALS rodent 
Figure 6. MO reduces the misfolded SOD1 protein. (A) Non-denaturing gel with misfolded specific antibody 
C4F6 demonstrates decrease levels of misfolded SOD1 protein in brain and in spinal cord of MO2 treated 
SODG93A adult mice (ICV, 40 nmoles, at P80) respect to scr-treated animals at different time-points. Denaturing 
gel for β -actin served as loading controls. WT: wild-type mice; SCR: scr-treated SODG93A mice; MO: MO-treated 
SODG93A mice. Experiment shown is representative of three independent trials. (B) Expression of misfolded 
specific antibody B8H10 (green) is reduced in the spinal cord of MO2-treated mice respect to scr-treated mice. 
Scale bar: 70 μ m. Nuclei are stained with DAPI (blue). SCR: scr-treated mice; MO2: mice treated with Bare-MO 
sequence 2, WT: wild-type mice. (C) The reduction is confirmed also in vitro in MO-treated fALS iPSC-derived 
MNs. Scale bar: 100 μ m. Nuclei are stained with DAPI (blue). SCR: scr-treated mice; MO2: mice treated with 
Bare-MO sequence 2, WT: wild-type mice.
www.nature.com/scientificreports/
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models, with an absence of adverse effects. Previous data involving transgenic mice have suggested that lowering 
endogenous SOD1 activity is safe33, and the recent clinical trial with the ASO ISIS 333611 confirms this notion 
in humans as well21. Moreover, the local delivery method used in our study can be performed in humans via 
local intrathecal injection, a clinically common procedure that was recently shown to be safe in the Phase 1 ISIS 
333611 clinical trial21. The non-invasive mode of vector delivery used in this study (local and intravenous) and 
the substantial efficacy achieved demonstrate the enormous and realistic potential to advance MO approaches to 
the clinic.
SOD1 can exist in an altered/abnormal conformation, referred to as misfolded SOD1, that is associated with 
the inherent toxic nature of SOD1 mutations10,36–38. In our study, we demonstrated that MO is able to decrease 
the misfolded form of SOD1 in the CNS of treated mice and in fALS iPSC-derived MNs in vitro. This result is 
extremely important because several reports have suggested that SOD1 misfolding is involved in sALS9. However, 
whether SOD1 is involved in sporadic disease remains controversial. In sALS, WT SOD1 can assume aberrant 
conformations that resemble those of mutant SOD1 in ALS; misfolded WT SOD1 can reproduce some of the 
cytotoxicity triggered by mutant SOD110–12. Importantly, these findings indicate that in a proportion of sALS 
patients, therapies aimed at reducing SOD1, including an MO-based approach, may be effective.
MO-based strategy can be applied to target other pathological molecular pathways in the symptomatic phase 
of ALS to achieve a therapeutic effect. Furthermore, MO silencing of a mutated gene may be equally applica-
ble to other dominantly inherited neurodegenerative disorders related to a toxic gain-of-function, such as 
α -synuclein-associated inherited forms of Parkinson’s disease or Huntington’s disease, in which depletion of the 
endogenous pathological protein could be curative.
Our data represent the first demonstration of the therapeutic efficacy and feasibility of MO-mediated gene 
silencing for ALS, both fALS and sALS, and for other neurodegenerative diseases. Moreover, our in vitro and 
in vivo experiments in murine and human models provide an excellent rationale for clinical translation to 
patients.
Materials and Methods
Morpholino oligomers. The MO sequence number 1 was GCACGCACACGGCCTTCGTCGCCAT and 
the number 2 was CACAGGCCTTCGTCGTCGCCATAACTC. These two MO sequences were synthesized 
as Bare-MO without any modifications or with an octa-guanidine modification (Gene Tools). The scr-MO 
sequences were designed based on the best control sequence predicted by the bioinformatic tool (Gene tools, 
www.gene-tools.com). MOs were dissolved in sterile saline solution at the appropriate concentration for injection.
Cell culture. iPSC lines were reprogrammed from fALS fibroblasts (L114P SOD1 mutation30) and healthy 
subjects (from Eurobiobank with appropriate ethical approval), using a non-viral protocol, as previously 
described29. To differentiate iPSCs into spinal MNs, we followed a multistep protocol developed for human 
embryonic stem cells (ESCs) and iPSCs28. Cells were plated with neuronal medium (Dulbecco’s modified Eagle’s 
medium (MEM)/F12 (Life Technologies), supplemented with MEM nonessential amino acids solution (Life 
Technologies), N2 (Life Technologies), and heparin (2 mg/ml; Sigma- Aldrich), to which retinoic acid (0.1 μ M; 
Sigma-Aldrich) was added after 10 days for neural caudalization. Posteriorized neuroectodermal cells were col-
lected at day 17 and suspended for a week in the same medium with retinoic acid (0.1 μ M) and Sonic hedgehog 
(100–200 ng/ml; R&D Systems), followed by the addition of BDNF and GDNF on day 24 (10 ng/ml; PeproTech). 
A centrifugation gradient was used to maximize motor neuron acquisition28. Cells were fixed and immunostained 
for quantification following seeding in culture for at least 24 h.
Immunocytochemistry of iPSCs and their derivatives. Cells were fixed in 4% paraformaldehyde for 
10 min, blocked with 10% BSA and permeabilized with 0.3% Triton X-100 in phosphate-buffered saline (PBS). We 
incubated the cells with primary antibodies for the pluripotency marker TRA1-60, SSEA-3 (1:100, BD, Cy3 conju-
gated), for the motor neuronal marker SMI32 (1:200; mouse, Millipore) or for apoptotic markers Bax (1:100, rab-
bit, Cell Signaling) Caspase-3 (1:100, rabbit, Cell Signaling) Caspase-8 (1:100, rabbit, Santa Cruz Biotechnology) 
overnight and with secondary antibodies anti-rabbit, anti-mouse FITC-conjugated (Dako, 1:100) for 1 h. For all 
imaging, we used a confocal LEICA LCS2 microscope. We quantified immunoreactivity score for apoptotic mark-
ers measuring the optical densities of each staining with ImageJ software at 30 days after the treatment.
MO transfection and MNs count in vitro. Hela and iPSCs were electroporated with the Neon 
Nucleofection System (Life Technologies) following the MO manufacturer instructions. Briefly, cells were 
trypsinized, counted and washed with PBS by centrifugation. The pellet was resuspended in 100 ul Resuspension 
Buffer R and 20 ug MO were added. The cell-MO mixture was aspirate with the Neon™ Pipette and electropo-
rated with the set pulse conditions on the device. Transfected cells were transfer on the prepared culture plate 
containing pre-warmed medium. Cells were harvested 48 h and 72 h after nucleofection. For MNs count: cells 
were treated with MO2 at day 0 and counted for survival analysis at day 1 and after 30 days. We quantified MNs 
using identification of Hb9::GFP29, counting 10 randomly selected fields/well (3 wells per condition per experi-
ment in five experiments).
Animal procedures. All transgenic animals were purchased from The Jackson Laboratory. All ani-
mal experiments were approved by the University of Milan and Italian Ministry of Health review boards, 
in compliance with US National Institutes of Health Guidelines45. We used transgenic mice of the strain 
B6.Cg-Tg(SOD1-G93A)1Gur/J, which carries a high copy number of the mutant human SOD1 allele contain-
ing a Gly93Ala (G93A) substitution. Progeny for experimental analyses was obtained by breeding SOD1G93A 
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transgenics with C57BL/6 wild-type mice. Transgenic mice were identified by polymerase chain reaction, as pre-
viously described45.
The Modified-MO was tested in adult mice with a systemic injection as recommended by the manufacturer. 
We treated symptomatic SOD1G93A transgenic mice (P120) with 12.5 mg/kg of Modified-MO administered IV 
twice in a week. Tissues were harvested the day after the second treatment. The Bare-MO and the Modified-MO 
were tested in pups, by injecting ICV at P0 (80 μ g) and intraperitoneally (IP) at P0, P3 and P6 (80 μ g/injections) 
in SOD1 mice and we collected tissues 2 or 4 weeks after the treatment for western blot analysis25. For western 
blot analysis Bare-MO2 was injected ICV in adult SOD1 mice at P80, 40 nMoles and the tissues harvested 2 weeks 
after the treatment.
For the survival analysis adult SOD1 mice were injected with Bare-MO (40 nMoles) at early symptomatic 
phase (at P85) with ICV injection follow the standard stereotactic coordinate and intravenously (IV, 12,5 mg/kg) 
according to Gene Tools instructions, once a week until the end of the disease.
Western blots. Western blot analysis was performed as previously described25. Briefly, frozen spinal cord 
specimen were homogenized in RIPA-buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deox-
ycholate and 0.1% SDS) supplemented with protease inhibitor cocktail tablets (Roche) and the protein content 
was measured using Lowry assay. An amount of 40 μ g of total protein was boiled in Laemmli buffer for 5 min and 
separated on a 8% sodium dodecyl sulfate–polyacrylamide gel electrophoresis SDS–PAGE. After electrophoresis, 
proteins were transferred on a nitrocellulose membrane, blocked in 5% BSA (for 1 hour at room temperature) 
and incubated with a primary anti-SOD-1 antibody (1:1200, R&D) overnight at 4 °C. The day after the nitrocel-
lulose membrane was incubated with anti-rabbit IgG conjugated to horseradish peroxidase (1:2700). Finally, the 
immune complexes were detected using chemiluminescent detection reagents. The nitrocellulose membrane was 
stripped and reprobed with anti-actin monoclonal antibody for equal loading control. For the quantification anal-
ysis of all western blot, the values showed were means ± SEM of SOD1:β -actin expression levels (n = 3).
Western blots for SOD misfolded protein. Samples for native western blot analysis were prepared in 
1X loading buffer ph 8.6 by sonication, 30 ug total protein were separated by PAGE with 12% Tris-Glycine gels in 
Tris-Glycine buffer at 4 °C. After 15 min of incubation in 0,1% SDS the proteins were transferred to Nitrocellulose 
in Transfer buffer pH 9.2 for 90 min at 4 °C. Membrane were air dry fixed and blocked for 1 hour at 25 °C in 5% 
non fat dry-milk , probed with C4F6 overnight at 4 °C followed by HRP-coniugated rabbit anti-Mouse IgG and 
visualized by chemiluminescence.
Neuromuscular evaluation and survival. All groups of SOD mice were monitored daily after treatment 
with MOs sequence or scramble for phenotypic hallmarks of disease. The investigators that executed the func-
tional assessment were blind to the treatment. Body weight was recorded weekly, and motor function was tested 
weekly with an accelerating rotarod device (4–40 rpm; Rota-Rod 7650; Ugo Basile). We recorded the length of 
time that each mouse remained on the rotarod. Mortality was scored as the age at death. The animals were sacri-
ficed when they were unable to right themself within 30 s when positioned in a supine position29. The examinators 
were blinded to the treatments.
Spinal cord analysis. Animals were euthanized at the end stage, perfused and fixed with 4%PFA in PBS 
(pH 7.4). The spinal cord was isolated, immersed in PFA for 1 hand then soaked overnight in 20% sucrose in PBS 
(pH 7.4). The fixed tissue was frozen in Tissue Tek OCT compound (Sakura) with liquid nitrogen. The tissues 
were cryosectioned and mounted on gelatinized glass slides. Every tenth 20 mm section was collected. All sec-
tions were blocked with 10% BSA and permeabilized with 0.3%Triton X-100in PBS. Sections were processed for 
multiple markers to determine inflammatory reaction. Primary antibodies were added overnight at 4 °C GFAP 
(1:200, mouse monoclonal Cy3 conjugate, Sigma), S100β (rabbit, 1:3000, Abcam), Iba-1 (rabbit, 1: 1500, Wako) 
and B8H10 (1:100, mouse, Medimabs). As secondary antibody anti-rabbit, anti-mouse FITC-conjugated (Dako, 
1:100) for 1.5 h at RT was used. Histological analysis for quantification of microglia and astrocytes was performed 
as described46, on an average of six sections of the lumbar spinal cord for each animal in each group were counted.
In vivo motor neuron and axon count. A group of mice was used for the histopathological analy-
sis (n = 3). The lumbar spinal cord region was processed for paraffin embedding. Serial cross sections (12 μ m 
thick) of the lumbar spinal cords were made, and every fifth section was processed and Nissl stained, as reported 
previously47. The number of all MNs counted in these cross sections (n = 50 for each mouse) were analyzed. 
The sections were analyzed at 20× magnification in the anterior horn (either left or right) for the presence of all 
neurons in that region. All cells were counted within the ventral horn below an arbitrary horizontal line drawn 
from the central canal. Only neuronal cells with at least 1 nucleolus located within the nucleus were counted, as 
previously described47.
The axonal count was performed as previously described on semi-thin transverse sections stained with 
toluidine blue48. L4 lumbar anterior roots were examined for axon counting on the optic microscope at 60× 
magnification.
Morphological analysis of the muscles. A group of mice was used for histological analysis of the periphery 
(n = 3). The nitrogen frozen quadriceps of the end-stage MO-treated, scr-treated or WT mice were cryosec-
tioned and stained for H&E to determine myofiber dimension as reported25. Approximately 500 non-overlapping 
myofibers from each muscle were randomly selected and photographed at 40× magnification.
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Statistical analysis. We used StatsDirect for Windows (version 2.6.4) for all analyses, and the null 
hypothesis was rejected at the 0.05 level. All counting data from immunocyto/histochemical analyses and cell 
survival were expressed as mean values ± SEM and statistically evaluated by one-way ANOVA followed by 
Tukey’s post-hoc analysis. We analyzed differences in the results of morphometric axonal length measurement 
(mean ± SEM for five independent experiments) with the Kolmogorov–Smirnov test (http://www.physics.csbsju.
edu/stats/KS-test.n.plot_form.html). Kaplan–Meier survival analysis and the log-rank test were used for survival 
comparisons. The growth curve and rotarod results were analyzed by ANOVA followed by a Tukey’s post-hoc 
analysis for multiple comparisons. Latency to fall was analyzed also using ANCOVA with body weight as the 
covariate.
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